"Checkpoint Kinase 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Enzyme activated in response to DNA DAMAGE involved in cell cycle arrest. The gene is located on the long (q) arm of chromosome 22 at position 12.1. In humans it is encoded by the CHEK2 gene.
Descriptor ID |
D064447
|
MeSH Number(s) |
D08.811.913.696.620.682.700.145
|
Concept/Terms |
Checkpoint Kinase 2- Checkpoint Kinase 2
- Kinase 2, Checkpoint
- Chk2 Protein Kinase
- Kinase, Chk2 Protein
- Protein Kinase, Chk2
- Checkpoint-Like Protein CHK2
- CHK2, Checkpoint-Like Protein
- Checkpoint Like Protein CHK2
- Protein CHK2, Checkpoint-Like
- Serine Threonine Protein Kinase Chk2
- LFS2 Protein Kinase
- Kinase, LFS2 Protein
- Protein Kinase, LFS2
- CHEK2 Kinase
- Kinase, CHEK2
- hCHK2 Kinase
- Kinase, hCHK2
- Serine-Threonine-Protein Kinase CHK2
- CHK2, Serine-Threonine-Protein Kinase
- Kinase CHK2, Serine-Threonine-Protein
- CDS1 Kinase
- Kinase, CDS1
- PP1425 Protein Kinase
- Kinase, PP1425 Protein
- Protein Kinase, PP1425
|
Below are MeSH descriptors whose meaning is more general than "Checkpoint Kinase 2".
Below are MeSH descriptors whose meaning is more specific than "Checkpoint Kinase 2".
This graph shows the total number of publications written about "Checkpoint Kinase 2" by people in this website by year, and whether "Checkpoint Kinase 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2001 | 0 | 1 | 1 |
2002 | 0 | 2 | 2 |
2003 | 0 | 1 | 1 |
2005 | 0 | 1 | 1 |
2006 | 0 | 1 | 1 |
2007 | 0 | 2 | 2 |
2010 | 0 | 1 | 1 |
2011 | 0 | 1 | 1 |
2013 | 0 | 1 | 1 |
2017 | 1 | 0 | 1 |
2018 | 2 | 0 | 2 |
2021 | 1 | 0 | 1 |
2022 | 0 | 2 | 2 |
2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Checkpoint Kinase 2" by people in Profiles.
-
Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2. J Clin Oncol. 2023 03 20; 41(9):1703-1713.
-
Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies. Curr Hematol Malig Rep. 2022 08; 17(4):94-104.
-
Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis. JAMA Oncol. 2022 04 01; 8(4):587-596.
-
Risk of Late-Onset Breast Cancer in Genetically Predisposed Women. J Clin Oncol. 2021 11 01; 39(31):3430-3440.
-
Clinical interpretation of pathogenic ATM and CHEK2 variants on multigene panel tests: navigating moderate risk. Fam Cancer. 2018 10; 17(4):495-505.
-
A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer. Prostate. 2018 06; 78(8):607-615.
-
Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer. JAMA Oncol. 2017 Sep 01; 3(9):1190-1196.
-
Germline rearrangements in families with strong family history of glioma and malignant melanoma, colon, and breast cancer. Neuro Oncol. 2014 Oct; 16(10):1333-40.
-
DNA resection proteins Sgs1 and Exo1 are required for G1 checkpoint activation in budding yeast. DNA Repair (Amst). 2013 Sep; 12(9):751-60.
-
PTEN positively regulates UVB-induced DNA damage repair. Cancer Res. 2011 Aug 01; 71(15):5287-95.